Breuer, Cort B.
Hanlon, Killian S.
Natasan, Jeya-shree
Volak, Adrienn
Meliani, Amine
Mingozzi, Federico
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Moon, James J. http://orcid.org/0000-0001-8246-931X
Maguire, Casey A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01-AI107020, DC017117)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 20 June 2019
Accepted: 28 February 2020
First Online: 11 March 2020
Competing interests
: C.A.M. has an issued patent as well as patent applications involving the exo-AAV platform. C.A.M. has a competing financial interest in Chameleon Biosciences, Inc., a company developing an enveloped Adeno Associated Virus (AAV) vector platform technology for repeated dosing of systemic gene therapy. C.A.M.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. B.P.K. is a co-inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies. F.M. is an employee of and holds equity in Spark Therapeutics. C.A.M, B.P.K. and F.M. declare no competing non-financial interests. C.B.B., J.J.M., KSH, JN, AV, and AM declare no competing financial and non-financial interests.